Terns Pharmaceuticals Inc Cash Flow Conversion Efficiency
Terns Pharmaceuticals Inc cash flow conversion efficiency. Based on the latest financial reports, Terns Pharmaceuticals Inc (TERN) has a cash flow conversion efficiency ratio of -0.070x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-19.77 Million) by net assets ($284.07 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Terns Pharmaceuticals Inc (2018–2024)
Cash flow conversion efficiency of Terns Pharmaceuticals Inc from 2018 to 2024. This chart illustrates how Terns Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View TERN stock price for real-time trading data and today's change.
Terns Pharmaceuticals Inc Cash Flow Conversion Ratio Explained
Terns Pharmaceuticals Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Terns Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Terns Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Also see Terns Pharmaceuticals Inc (TERN) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Lotte Himart
KO:071840
|
0.087x |
|
Veracruz Properties SOCIMI SA
MC:YVCP
|
0.025x |
|
Immobile
WAR:GKI
|
0.215x |
|
Mountain Crest Acquisition 6 Corp. Ordinary Shares
NASDAQ:MCAH
|
N/A |
|
AXON PARTNERS GRP EO -10
F:XE1
|
N/A |
|
Axcen Photonics
TWO:6530
|
0.067x |
|
Fabryki Mebli Forte S.A.
WAR:FTE
|
0.029x |
|
Shotspotter Inc
NASDAQ:SSTI
|
0.062x |
Annual Cash Flow Conversion Efficiency for Terns Pharmaceuticals Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Terns Pharmaceuticals Inc from 2018 to 2024. Review Terns Pharmaceuticals Inc financial flexibility index to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $345.87 Million | $-70.02 Million | -0.202x | +23.29% |
| 2023-12-31 | $255.37 Million | $-67.39 Million | -0.264x | -48.82% |
| 2022-12-31 | $276.94 Million | $-49.11 Million | -0.177x | +32.04% |
| 2021-12-31 | $160.30 Million | $-41.83 Million | -0.261x | +39.96% |
| 2020-12-31 | $68.59 Million | $-29.81 Million | -0.435x | +87.97% |
| 2019-12-31 | $18.32 Million | $-66.22 Million | -3.614x | -1344.50% |
| 2018-12-31 | $72.23 Million | $-18.07 Million | -0.250x | -- |
About Terns Pharmaceuticals Inc
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hor… Read more